Even if it's not a huge purchase, we think it was good to see that Dag Andersson, the President & CEO of Xvivo Perfusion AB (publ) (STO:XVIVO) recently shelled out kr105k to buy stock, at kr322 per share. However, it only increased their shares held by 1.3%, and it wasn't a huge purchase by absolute value, either.
The Last 12 Months Of Insider Transactions At Xvivo Perfusion
Over the last year, we can see that the biggest insider sale was by the COO & Deputy CEO, Christoffer Rosenblad, for kr1.6m worth of shares, at about kr388 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. It's of some comfort that this sale was conducted at a price well above the current share price, which is kr336. So it may not tell us anything about how insiders feel about the current share price. Christoffer Rosenblad was the only individual insider to sell shares in the last twelve months.
You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership of Xvivo Perfusion
Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Xvivo Perfusion insiders own about kr241m worth of shares. That equates to 2.4% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
What Might The Insider Transactions At Xvivo Perfusion Tell Us?
It is good to see the recent insider purchase. But we can't say the same for the transactions over the last 12 months. The high levels of insider ownership, and the recent buying by an insider suggests they are well aligned and optimistic. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Xvivo Perfusion. To assist with this, we've discovered 2 warning signs that you should run your eye over to get a better picture of Xvivo Perfusion.
Of course Xvivo Perfusion may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.